Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of the shares of Class A common stock are being offered by Recursion. In addition, Recursion intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock offered. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Recursion Announces Proposed Offering of Class A Common Stock

Recursion Pharmaceuticals (RXRX) reachead $9.38 at the closing of the latest trading day, reflecting a +0.43% change compared to its last close.

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with Recursion Pharmaceuticals (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to industrialize drug discovery. Recursion will have access to de-identified clinico-genomic data, collected from research participants who consent to participate in Helix's extensive research network, wh.

Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data

SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, analysts, and other stakeholders during Download Day, Recursion's investor and R&D day, on Monday, June 24, 2024.

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

This thesis makes the case for an investment in Recursion Pharmaceuticals operating as a TechBio which "industrializes" the process of drug discovery in contrast to a typical biotech. The difference between TechBio and biotech may appear subtle, but is an important one that may have motivated Nvidia to invest $50 million. Based on the value of its platform and data assets, it is a buy with a 48.5% upside potential.

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and strategic partnerships with biopharmaceutical companies. While Recursion is probably the best positioned AI drug discovery company, the stock could pull back if AI hype fades.

Recursion Pharmaceuticals: Unprecedented Scale

Altimmune

EVgo

Low-priced stocks under $10 can be explosively awarding. That is, if you spot the right one at the right time with the right catalyst.

3 Stocks Under $10 Set to Quadruple by 2025: June Edition

NVIDIA

ARM Holdings PLC

Nano-X Imaging

SoundHound AI Inc

Nvidia has been one of the best-performing stocks on Wall Street since 2023, amassing holdings in four companies along the way.

Nvidia Owns These 4 Stocks. Here's How They're Doing.

Recursion hopes to transform the healthcare industry with its innovative drug discovery platform. The small company has gained the interest of Nvidia, which has invested in the business.

Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim

Fabrinet

The AI craze may be slowing, but that doesn't mean there's not plenty of opportunity available. While investing heavily in Nvidia (NASDAQ: NVDA ) could keep the cash coming in (considering its recent performance), there's a more cost-effective strategy to leverage Nvidia's growth: investing in Nvidia partner stocks, which stand to benefit from Nvidia's expansive influence across various industries.

Nvidia's Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance

Viking Therapeutics

Biotechs that aspire to be disruptive are quite risky. However, they do offer the chance of disproportionate rewards.

1 Disruptive Biotech Stock to Buy Now, and 1 to Consider

Cathie Wood Owns These 2 AI Stocks. Should You?

Recursion Pharmaceuticals hopes to use AI to accelerate drug discovery in the healthcare industry. its ambitious plans are still unproven, and the business has no approved products of its own.

Is Recursion Pharmaceuticals Stock a Millionaire-Maker?

Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm. Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in CRISPR-Cas9 gene knockouts and a debiasing (correcting) algorithm.

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

Serve Robotics Inc

You're doing something right if your company is worth $2.6 trillion like Nvidia. And it's worth looking at the companies Nvidia invests in.

Nvidia Owns 4 Stocks — One Is Doing Even Better Than It Is

Ginkgo Bioworks Holdings

Cathie Wood likes to invest in risky biotech stocks. Ginkgo Bioworks has ambitions to disrupt biopharma manufacturing.

2 Cathie Wood Biotech Stocks That Could Be Worth the Risk

Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

Viking Therapeutics is looking to make noise in a fast-growing therapeutic area. Recursion Pharmaceuticals' approach could change the way we develop drugs.

2 Stocks That Could 10x by 2035

Recursion Pharmaceuticals (RXRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock

Schrodinger 

Some high-tech biotechs claim to be "TechBio" companies. The term signals the use of an automation-heavy approach to biotech.

What's the Difference Between Biotech Stocks and TechBio Stocks?

BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

Recursion Pharmaceuticals, an AI-focused biotech, makes up more than 5% of one of Ark Invest's ETFs. The company's approach looks promising, but it has yet to produce the kinds of results investors want.

Cathie Wood Is Buying This Under-the-Radar AI Stock

Recursion Pharmaceuticals reported higher revenue than analysts expected for Q1 2024. The company has made significant advancements in its clinical pipeline, with multiple Phase 2 trials expected to read out starting in Q3 2024.

Recursion Pharma's Q1 Earnings Beat Estimates

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Conference Call Participants Chris Gibson Hi, everybody. I'm Chris Gibson, Co-Founder and CEO of Recursion, and I'm so delighted you've joined us today for our Q1 2024 Earnings Call -- L(earnings) Call, as we call it.

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.34 per share a year ago.

News for Recursion Pharmaceuticals Stock (RXRX)